questionsmedicales.fr
Acides aminés, peptides et protéines
Protéines
Protéines et peptides de signalisation intracellulaire
Protein-Serine-Threonine Kinases
Mitogen-Activated Protein Kinases
JNK Mitogen-Activated Protein Kinases
JNK Mitogen-Activated Protein Kinases : Questions médicales fréquentes
Termes MeSH sélectionnés :
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "JNK Mitogen-Activated Protein Kinases : Questions médicales les plus fréquentes",
"headline": "JNK Mitogen-Activated Protein Kinases : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les JNK Mitogen-Activated Protein Kinases : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-02-10",
"dateModified": "2025-05-05",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "JNK Mitogen-Activated Protein Kinases"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Mitogen-Activated Protein Kinases",
"url": "https://questionsmedicales.fr/mesh/D020928",
"about": {
"@type": "MedicalCondition",
"name": "Mitogen-Activated Protein Kinases",
"code": {
"@type": "MedicalCode",
"code": "D020928",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.476.563.567"
}
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Mitogen-Activated Protein Kinase 8",
"alternateName": "Mitogen-Activated Protein Kinase 8",
"url": "https://questionsmedicales.fr/mesh/D048055",
"about": {
"@type": "MedicalCondition",
"name": "Mitogen-Activated Protein Kinase 8",
"code": {
"@type": "MedicalCode",
"code": "D048055",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.476.563.567.374.500"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Mitogen-Activated Protein Kinase 9",
"alternateName": "Mitogen-Activated Protein Kinase 9",
"url": "https://questionsmedicales.fr/mesh/D048056",
"about": {
"@type": "MedicalCondition",
"name": "Mitogen-Activated Protein Kinase 9",
"code": {
"@type": "MedicalCode",
"code": "D048056",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.476.563.567.374.750"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Mitogen-Activated Protein Kinase 10",
"alternateName": "Mitogen-Activated Protein Kinase 10",
"url": "https://questionsmedicales.fr/mesh/D048057",
"about": {
"@type": "MedicalCondition",
"name": "Mitogen-Activated Protein Kinase 10",
"code": {
"@type": "MedicalCode",
"code": "D048057",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.476.563.567.374.800"
}
}
}
],
"about": {
"@type": "MedicalCondition",
"name": "JNK Mitogen-Activated Protein Kinases",
"alternateName": "JNK Mitogen-Activated Protein Kinases",
"code": {
"@type": "MedicalCode",
"code": "D048031",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Mohammad Shafiq",
"url": "https://questionsmedicales.fr/author/Mohammad%20Shafiq",
"affiliation": {
"@type": "Organization",
"name": "From the Division of Pharmacology (M.S., K.J., K.H.), CSIR-Central Drug Research Institute, Lucknow, India."
}
},
{
"@type": "Person",
"name": "Kumaravelu Jagavelu",
"url": "https://questionsmedicales.fr/author/Kumaravelu%20Jagavelu",
"affiliation": {
"@type": "Organization",
"name": "From the Division of Pharmacology (M.S., K.J., K.H.), CSIR-Central Drug Research Institute, Lucknow, India."
}
},
{
"@type": "Person",
"name": "Neeraj Kumar Verma",
"url": "https://questionsmedicales.fr/author/Neeraj%20Kumar%20Verma",
"affiliation": {
"@type": "Organization",
"name": "Division of Molecular and Structural Biology (N.K.V., J.K.G.), CSIR-Central Drug Research Institute, Lucknow, India."
}
},
{
"@type": "Person",
"name": "Jimut Kanti Ghosh",
"url": "https://questionsmedicales.fr/author/Jimut%20Kanti%20Ghosh",
"affiliation": {
"@type": "Organization",
"name": "Division of Molecular and Structural Biology (N.K.V., J.K.G.), CSIR-Central Drug Research Institute, Lucknow, India."
}
},
{
"@type": "Person",
"name": "Matthias Gaestel",
"url": "https://questionsmedicales.fr/author/Matthias%20Gaestel",
"affiliation": {
"@type": "Organization",
"name": "Institute for Zellbiochemie, Medizinische Hochschule Hannover (MHH), Hanover, Germany (M.G.)."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "The prognostic implication of visual acuity at the time of uveal melanoma diagnosis.",
"datePublished": "2022-11-24",
"url": "https://questionsmedicales.fr/article/36434284",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1038/s41433-022-02316-8"
}
},
{
"@type": "ScholarlyArticle",
"name": "Association of macular OCT and OCTA parameters with visual acuity in glaucoma.",
"datePublished": "2022-09-09",
"url": "https://questionsmedicales.fr/article/36126109",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1136/bjo-2022-321460"
}
},
{
"@type": "ScholarlyArticle",
"name": "Successful Aging in Assisted Living: The Importance of Near Visual Acuity.",
"datePublished": "2022-09-01",
"url": "https://questionsmedicales.fr/article/36007216",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3928/00989134-20220805-01"
}
},
{
"@type": "ScholarlyArticle",
"name": "Characterization of vision in pediatric retinoblastoma survivors beyond visual acuity.",
"datePublished": "2023-07-12",
"url": "https://questionsmedicales.fr/article/37442536",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.jaapos.2023.06.003"
}
},
{
"@type": "ScholarlyArticle",
"name": "The speed acuity test as a diagnostic aid in cerebral visual impairment.",
"datePublished": "2022-06-22",
"url": "https://questionsmedicales.fr/article/35732797",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1038/s41598-022-14673-1"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Acides aminés, peptides et protéines",
"item": "https://questionsmedicales.fr/mesh/D000602"
},
{
"@type": "ListItem",
"position": 3,
"name": "Protéines",
"item": "https://questionsmedicales.fr/mesh/D011506"
},
{
"@type": "ListItem",
"position": 4,
"name": "Protéines et peptides de signalisation intracellulaire",
"item": "https://questionsmedicales.fr/mesh/D047908"
},
{
"@type": "ListItem",
"position": 5,
"name": "Protein-Serine-Threonine Kinases",
"item": "https://questionsmedicales.fr/mesh/D017346"
},
{
"@type": "ListItem",
"position": 6,
"name": "Mitogen-Activated Protein Kinases",
"item": "https://questionsmedicales.fr/mesh/D020928"
},
{
"@type": "ListItem",
"position": 7,
"name": "JNK Mitogen-Activated Protein Kinases",
"item": "https://questionsmedicales.fr/mesh/D048031"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : JNK Mitogen-Activated Protein Kinases - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur JNK Mitogen-Activated Protein Kinases",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-13",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur JNK Mitogen-Activated Protein Kinases",
"description": "Comment diagnostiquer une activation des JNK ?\nQuels biomarqueurs indiquent l'activation des JNK ?\nLes tests génétiques sont-ils utiles pour les JNK ?\nQuels examens d'imagerie sont utilisés pour les JNK ?\nPeut-on mesurer l'activité des JNK dans le sang ?",
"url": "https://questionsmedicales.fr/mesh/D048031?mesh_terms=Visual+Acuity&page=3#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur JNK Mitogen-Activated Protein Kinases",
"description": "Quels symptômes sont liés à l'activation des JNK ?\nLes JNK sont-ils impliqués dans des maladies ?\nComment les JNK affectent-ils la douleur ?\nLes JNK influencent-ils le métabolisme ?\nY a-t-il des symptômes neurologiques associés aux JNK ?",
"url": "https://questionsmedicales.fr/mesh/D048031?mesh_terms=Visual+Acuity&page=3#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur JNK Mitogen-Activated Protein Kinases",
"description": "Comment prévenir l'activation des JNK ?\nLe stress influence-t-il les JNK ?\nLes antioxydants aident-ils à prévenir l'activation des JNK ?\nL'exercice physique prévient-il l'activation des JNK ?\nLes habitudes alimentaires influencent-elles les JNK ?",
"url": "https://questionsmedicales.fr/mesh/D048031?mesh_terms=Visual+Acuity&page=3#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur JNK Mitogen-Activated Protein Kinases",
"description": "Quels traitements ciblent les JNK ?\nLes anti-inflammatoires affectent-ils les JNK ?\nLa thérapie génique peut-elle cibler les JNK ?\nLes traitements naturels influencent-ils les JNK ?\nLes traitements anticancéreux ciblent-ils les JNK ?",
"url": "https://questionsmedicales.fr/mesh/D048031?mesh_terms=Visual+Acuity&page=3#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur JNK Mitogen-Activated Protein Kinases",
"description": "Quelles complications sont liées à l'activation des JNK ?\nLes JNK sont-ils liés à des complications cardiovasculaires ?\nLes JNK influencent-ils le vieillissement cellulaire ?\nY a-t-il des complications neurologiques liées aux JNK ?\nLes JNK sont-ils impliqués dans des complications métaboliques ?",
"url": "https://questionsmedicales.fr/mesh/D048031?mesh_terms=Visual+Acuity&page=3#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur JNK Mitogen-Activated Protein Kinases",
"description": "Quels facteurs de risque influencent les JNK ?\nL'alimentation affecte-t-elle les JNK ?\nLe tabagisme influence-t-il les JNK ?\nL'exposition à des toxines affecte-t-elle les JNK ?\nLe manque d'exercice est-il un facteur de risque pour les JNK ?",
"url": "https://questionsmedicales.fr/mesh/D048031?mesh_terms=Visual+Acuity&page=3#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer une activation des JNK ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests de signalisation cellulaire et des analyses protéomiques peuvent être utilisés."
}
},
{
"@type": "Question",
"name": "Quels biomarqueurs indiquent l'activation des JNK ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des niveaux élevés de protéines phosphorylées c-Jun peuvent indiquer une activation."
}
},
{
"@type": "Question",
"name": "Les tests génétiques sont-ils utiles pour les JNK ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des tests peuvent identifier des mutations affectant la voie JNK."
}
},
{
"@type": "Question",
"name": "Quels examens d'imagerie sont utilisés pour les JNK ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'imagerie par résonance magnétique peut aider à visualiser des effets cellulaires."
}
},
{
"@type": "Question",
"name": "Peut-on mesurer l'activité des JNK dans le sang ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des échantillons sanguins peuvent être analysés pour des marqueurs d'activation."
}
},
{
"@type": "Question",
"name": "Quels symptômes sont liés à l'activation des JNK ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'activation peut entraîner inflammation, apoptose et dysfonction cellulaire."
}
},
{
"@type": "Question",
"name": "Les JNK sont-ils impliqués dans des maladies ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, ils sont associés à des maladies comme le cancer et les maladies neurodégénératives."
}
},
{
"@type": "Question",
"name": "Comment les JNK affectent-ils la douleur ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Ils modulent la signalisation de la douleur, contribuant à des douleurs chroniques."
}
},
{
"@type": "Question",
"name": "Les JNK influencent-ils le métabolisme ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, ils jouent un rôle dans la régulation du métabolisme énergétique."
}
},
{
"@type": "Question",
"name": "Y a-t-il des symptômes neurologiques associés aux JNK ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des troubles cognitifs et des troubles de l'humeur peuvent être observés."
}
},
{
"@type": "Question",
"name": "Comment prévenir l'activation des JNK ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un mode de vie sain, incluant une alimentation équilibrée et de l'exercice, peut aider."
}
},
{
"@type": "Question",
"name": "Le stress influence-t-il les JNK ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le stress oxydatif peut activer les JNK, donc la gestion du stress est cruciale."
}
},
{
"@type": "Question",
"name": "Les antioxydants aident-ils à prévenir l'activation des JNK ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les antioxydants peuvent réduire le stress oxydatif et l'activation des JNK."
}
},
{
"@type": "Question",
"name": "L'exercice physique prévient-il l'activation des JNK ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'exercice régulier peut moduler positivement l'activité des JNK."
}
},
{
"@type": "Question",
"name": "Les habitudes alimentaires influencent-elles les JNK ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une alimentation riche en nutriments peut réduire l'activation des JNK."
}
},
{
"@type": "Question",
"name": "Quels traitements ciblent les JNK ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des inhibiteurs spécifiques des JNK sont en développement pour diverses maladies."
}
},
{
"@type": "Question",
"name": "Les anti-inflammatoires affectent-ils les JNK ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certains anti-inflammatoires peuvent moduler l'activité des JNK."
}
},
{
"@type": "Question",
"name": "La thérapie génique peut-elle cibler les JNK ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "La thérapie génique est explorée pour corriger des dysfonctionnements des JNK."
}
},
{
"@type": "Question",
"name": "Les traitements naturels influencent-ils les JNK ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines plantes médicinales peuvent avoir un effet sur l'activation des JNK."
}
},
{
"@type": "Question",
"name": "Les traitements anticancéreux ciblent-ils les JNK ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des traitements anticancéreux visent à inhiber les voies JNK dans les cellules tumorales."
}
},
{
"@type": "Question",
"name": "Quelles complications sont liées à l'activation des JNK ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'activation excessive des JNK peut entraîner des maladies inflammatoires et cancéreuses."
}
},
{
"@type": "Question",
"name": "Les JNK sont-ils liés à des complications cardiovasculaires ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'activation des JNK est associée à des maladies cardiovasculaires."
}
},
{
"@type": "Question",
"name": "Les JNK influencent-ils le vieillissement cellulaire ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, une activation prolongée des JNK peut accélérer le vieillissement cellulaire."
}
},
{
"@type": "Question",
"name": "Y a-t-il des complications neurologiques liées aux JNK ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'activation des JNK est impliquée dans des troubles neurodégénératifs."
}
},
{
"@type": "Question",
"name": "Les JNK sont-ils impliqués dans des complications métaboliques ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, ils sont liés à des troubles métaboliques comme le diabète."
}
},
{
"@type": "Question",
"name": "Quels facteurs de risque influencent les JNK ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le stress, l'inflammation chronique et l'obésité sont des facteurs de risque connus."
}
},
{
"@type": "Question",
"name": "L'alimentation affecte-t-elle les JNK ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, une alimentation riche en graisses saturées peut augmenter l'activation des JNK."
}
},
{
"@type": "Question",
"name": "Le tabagisme influence-t-il les JNK ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le tabagisme est un facteur de risque qui peut activer les JNK."
}
},
{
"@type": "Question",
"name": "L'exposition à des toxines affecte-t-elle les JNK ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'exposition à des toxines environnementales peut activer les JNK."
}
},
{
"@type": "Question",
"name": "Le manque d'exercice est-il un facteur de risque pour les JNK ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, un mode de vie sédentaire peut augmenter le risque d'activation des JNK."
}
}
]
}
]
}
Visual outcomes after primary tumour treatment of uveal melanoma (UM) have been investigated repeatedly. This study evaluates the correlation between best-corrected visual acuity (BCVA) before treatme...
Pre-treatment BCVA was examined in relation to tumour dimensions and location, and survival in a retrospective cohort of 1809 patients who underwent plaque brachytherapy. BCVA was also correlated to t...
The mean BCVA of the tumour eye prior to plaque brachytherapy was LogMAR 0.42 (SD 0.46). Patients with low BCVA (LogMAR ≥ 1.00) did not differ in age (p = 0.19) and had similar frequency of ciliary bo...
UM patients with low BCVA before primary tumour treatment have a worse prognosis, likely related to increased tumour dimensions. Future studies should examine the prognostic significance of BCVA in re...
To investigate the association of macular optical coherence tomography (OCT)/OCT angiography (OCTA) parameters with visual acuity (VA) in glaucoma....
144 pseudophakic primary open-angle glaucoma eyes were included. Foveal (fVD), parafoveal (pf), perifoveal (perifVD) and whole-image vessel densities (wiVD) of superficial and deep layers, and their c...
In early glaucoma (80 eyes), no parameter correlated with VA. In moderate-advanced glaucoma (64 eyes), greater FAZ area (β=0.228) and circumference (β=0.063) correlated with worse VA (p<0.05), but not...
Some macular OCT/OCTA parameters were associated with VA in moderate-advanced, but not early glaucoma. These structural parameters may help identify glaucoma patients with impaired vision and reduced ...
NCT00221897....
Successful aging among independent community-dwelling older adults and those in residential settings is paramount to aging in place. The purpose of the current study was to explore how sensory, cognit...
Retinoblastoma (RB) and its associated treatments can significantly impact visual acuity. However, little is known regarding other measures of vision, such as contrast sensitivity or saccades. The aim...
This cross-sectional study included children aged 5-17 years who had completed treatment for RB. Visual acuity, saccades via fixation analysis, and contrast sensitivity by Cardiff contrast sensitivity...
Eleven children were enrolled (mean age, 10.7 ± 3.9 years). Treatment included enucleation (8 children [73%]) and chemotherapy (10 [91%]). Of the 11, one participant was unable to complete testing of ...
Decreased contrast sensitivity and impaired saccades were universally observed in this cohort of RB survivors. Comprehensive visual evaluation should be considered for all RB survivors to provide opti...
One of the characteristics of children with cerebral visual impairments (CVI) is that they need more time to process visual information. However, currently, few tests are available that can reliably m...
In order to determine the effect of nystagmus on objective visual acuity (VA) estimates, we compared subjective (VA...
To evaluate the causative and risk factors for optic neuropathy with mucocele via imaging studies....
We included 21 patients with rhinogenous optic neuropathy with mucocele. We collected data on the sinus involved, age, sex, number of days from the onset of visual impairment to surgery, and computed ...
After surgery, visual acuity improved in 16/21 (76.2%) patients, and a correlation analysis showed a significant positive correlation between pre-operative and post-operative visual acuity. In imaging...
Imaging studies of optic neuropathy with mucocele help to determine the risk factors and perform early and precise diagnostic imaging and decision-making for surgery....
This study investigated the long-term visual acuity (VA) outcome in the eyes of children with uveitis and severe visual impairment (SVI; VA ≤ 20/200) at presentation. Fifty-one children [57 eyes; medi...
Despite advances in surgical techniques, cataract remains the leading cause of preventable blindness, and massive surgeries have been adopted as a strategy to change this situation. Monitoring the res...
This is a prospective and longitudinal study in which translation, cultural adaptation and validation of the visual function (VF) and quality of life (QoL) questionnaire were performed. The appearance...
VF and QoL questionnaires showed one-dimension, good values of TLI (0.973, 0.951) and SRMR (0.057, 0.054), and for each item, weights > 0.7, H2 > 0.5, ranges > 5.8 and the RMSEA < 0.08. Correlations f...
The cataract surgery outcomes are outside the WHO recommendations regarding VA, but they have had a great impact on improving VF and QoL. The questionnaires showed excellent psychometric properties an...
We make use of expected information gain to quantify the amount of knowledge obtained from measurements in a population. In the first application, we compared the expected information gain in the Snel...